

UCLA

UCLA Previously Published Works

Title

Pre-pubertal and Pubertal Endocrine Disrupting Chemicals Exposure and Breast Density among Chilean Adolescents

Permalink

<https://escholarship.org/uc/item/2wx0j98d>

Journal

Cancer Epidemiology Biomarkers & Prevention, 27(12)

ISSN

1055-9965

Authors

Binder, Alexandra M
Corvalan, Camila
Pereira, Ana
[et al.](#)

Publication Date

2018-12-01

DOI

10.1158/1055-9965.epi-17-0813

Peer reviewed



HHS Public Access

Author manuscript

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2019 December 01.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2018 December ; 27(12): 1491–1499. doi:
10.1158/1055-9965.EPI-17-0813.

Prepubertal and Pubertal Endocrine-Disrupting Chemical Exposure and Breast Density among Chilean Adolescents

Alexandra M. Binder¹, Camila Corvalan², Ana Pereira², Antonia M. Calafat³, Xiaoyun Ye^{3,†}, John Shepherd⁴, and Karin B. Michels^{1,*}

¹Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, CA, USA

²Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile

³Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA

⁴Population Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu, Hawaii.

Abstract

Background: During puberty, mammary tissue undergoes rapid development, which provides a window of heightened susceptibility of breast composition to the influence of endogenous and exogenous hormones. Exposure to endocrine disrupting chemicals (EDCs) may affect breast development and composition and the risk of developing breast cancer in adulthood.

Methods: We evaluated the associations between breast density and urinary concentrations of phenols and phthalates collected at Tanner 1 (B1) and Tanner 4 (B4) in 200 Chilean girls. Total breast volume (BV), fibroglandular volume (FGV), and percent dense breast (%FGV) were evaluated at B4 using dual x-ray absorptiometry. Generalized estimating equations were used to analyze the association between concentrations of EDC biomarkers across puberty and breast density.

Results: The geometric mean %FGV was 7% higher among girls in the highest relative to the lowest tertile of monocarboxyisooctyl phthalate (1.07; 95% CI: 1.01–1.14). Monoethyl phthalate concentrations at B4 were positively associated with FGV (highest vs lowest tertile: 1.22; 95% CI: 1.06–1.40). Bisphenol A displayed a u-shaped association with FGV; girls in the middle tertile had at least 10% lower FGV than girls in the lowest or highest tertiles. Monocarboxyisononyl phthalate showed a non-linear association with BV. No other statistically significant associations were observed.

* **Corresponding Author:** Karin B. Michels, Department of Epidemiology, UCLA Fielding School of Public Health, 650 Charles Young Drive, South, Room 71-264 CHS, Los Angeles, CA 90095, USA. Telephone: (310) 825-8579. Fax: (310) 206-6039, k.michels@ucla.edu.

†deceased

Conflicts of Interests: The authors declare no potential conflicts of interest.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the US Department of Health and Human Services.

Conclusions: Our results suggest that the developing breast tissue is susceptible to select EDCs during childhood and adolescence.

Impact: This study may spur further investigations into environmental influences on breast development during puberty, and how shifts in pubertal breast density track through the life course to modify breast cancer risk.

Keywords

puberty; breast density; phenols; phthalates; endocrine disrupting chemicals

INTRODUCTION

High mammographic density is strongly associated with increased breast cancer risk (1–3). A greater proportion of dense breast tissue is indicative of relatively more collagen, epithelial and stromal cells relative to fat (4). Increasing age, parity, and menopause are all associated with reductions in breast density, reflecting a shift in the relative abundance of these cell types (5). Greater body fatness during childhood and adolescence has been associated with decreased adult breast density (6,7). Total breast volume of young women, estimated by cup size, has also been associated with breast cancer risk (8,9). Results from these studies suggest that breast density is modifiable, but largely dependent on initial peak density established during adolescence (10). Furthermore, it is during this period of rapid development and cell proliferation that the susceptibility of mammary tissue to carcinogens is suspected to be the greatest (11–13).

Pubertal breast development follows a coordinated surge in adrenal hormones preceding the reactivation of hypothalamic-pituitary-ovarian axis, and production of estrogen from the ovaries (14). Accordingly, during this period of rapid hormone-sensitive development, mammary tissue may be particularly susceptible to endocrine disrupting chemicals (EDCs), which have the potential to interfere with the action of the body's endogenous hormones (15). Phenols and phthalates are two classes of pervasive EDCs found in plastics, personal care products, adhesives, detergents, pharmaceuticals, and building materials (16–18). Despite their ubiquity, there are surprisingly few investigations into the potential impact of these compounds on human breast development and subsequent cancer risk. One prior longitudinal study of girls from the United States reported no association between childhood phthalate biomarkers in urine and the age of breast development (thelarche) (19). Within the same cohort, phenol urinary biomarkers demonstrated a more complicated relations with age at thelarche. While benzophenone-3 was associated with earlier thelarche, 2,5-dichlorophenol and triclosan were associated with later development (20). Only one study has investigated the potential association between phthalate exposure and breast cancer risk. In a case-control study of Mexican women, urinary concentrations of monoethyl phthalate (MEP) were associated with increased odds of premenopausal breast cancer, whereas monobenzyl phthalate (MBzP) and mono(3-carboxypropyl) phthalate (MCPP) were associated with lower odds (21).

These prior studies suggest that pubertal breast development might be sensitive to EDC exposure. However, no studies have explored how breast composition responds to EDC

exposure during childhood and adolescence. To address these gaps in knowledge, we investigated the association between childhood and adolescent EDC urinary biomarkers and pubertal breast density in a longitudinal cohort of girls in Santiago, Chile. This study provides unique insight into the potential influence of early life exposures on determinants of breast cancer risk.

MATERIALS AND METHODS

Study Population

Our study population was the longitudinal Growth and Obesity Cohort Study (GOCS) in Santiago, Chile. Initiated in 2006, children ages 2.6 to 4.0 years were recruited from public nursery schools of six counties in Santiago who met the following inclusion criteria: 1) singletons born in 2002–2003 and with birthweight between 2500 and 4500g, and 2) absence of physical (e.g. skin burn), medical (e.g. brain tumor) or endocrine diseases (e.g. hyperthyroidism, hyperprolactinemia) that can alter the growth and/or onset of puberty. Of 1,498 eligible participants, 1,195 (~80%) agreed to participate in the study. No significant differences in age, gender, and birth anthropometry were identified between the final participants and those not enrolled. The GOCS children are representative of the low to middle-income families served by the public nursery schools. Two trained dietitians collected anthropometry measurements approximately every 6 months after 2006. Based on height (cm) and weight (kg) measured at each clinic visit, sex and age-adjusted BMI Z-scores were calculated using the Centers for Disease Control and Prevention (CDC) growth charts. Of the 515 girls who participated in the original cohort, 389 girls had follow-up information through B4 and consented to have breast density measured using dual x-ray absorptiometry. Due to the limits in available funds, the current study was restricted to a subset of 200 randomly sampled girls with urine samples collected at both Tanner 1 (B1) and Tanner 4 (B4), and with breast density measurements performed at B4. Among the 389 girls with breast density measurements, total breast volume, fibroglandular volume, and percent dense breast adjusting for BMI Z-score at B4 did not significantly differ between those included and excluded from the current analysis. The study protocol was conducted in accordance with the Declaration of Helsinki guidelines and was approved by the Ethics Committee of the Institute of Nutrition and Food Technology, University of Chile and the Institutional Review Board of the Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Informed written consent was obtained from all parents or guardians of children before the start of data collection.

Breast Density Measurements

Breast density was measured at B4, when total fibroglandular volume is assumed to reach its peak (22). Breast development was assessed by visual inspection using the Tanner rating scale approximately every 6 months (23). After confirming the absence of pregnancy by a urine test, DXA was used to measure dense tissue volume (absolute fibroglandular volume) of the breast. The UCSF DXA breast scanning protocol was developed by Shepherd *et al.*, in the Department of Radiology and Biomedical Imaging, University of California, San Francisco (version 5) (24). Each breast was scanned using the Prodigy DXA system software (version 13.6, series 200674; GE Healthcare). A quality control phantom

containing reference breast density materials was scanned throughout the study to assure a stable calibration. This approach has been shown to have high validity and precision for measuring breast density in girls at different Tanner stages (22). The radiation dose from DXA is exceedingly small; DXA is commonly used to measure whole body percent fat and body mass in pediatric studies (25). Total projected breast area was manually delineated on each image and breast fibroglandular volume (FGV; cm³) and total volume (BV; cm³) was estimated using a two-compartment model of adipose and fibro-glandular tissue with software developed by Shepherd at the University of California (26). Percent FGV (%FGV) was defined as the proportion FGV relative to BV times 100. We averaged the values of the left and right breast for all analyses.

EDC Measurements

Fasting spot urine samples were collected between 10 AM and 12 PM in polypropylene sterile cups, immediately vortexed, and aliquoted, and stored at -20 °C until analysis. Previous evaluations indicate that the integrity of the specimens and stability of the biomarkers are not compromised under these conditions (27,28). Concentrations of 26 phenols and phthalates biomarkers were quantified in urines collected at B1 and B4 from 200 girls (400 urine samples). Biomarker measurements were performed at the CDC using described analytical methods; each analytic batch includes reagent blanks and low- and high-concentration quality control materials, which are evaluated using standard statistical probability rules (29,30). Concentrations below the limit of detection (LOD) were given an imputed value equal to LOD/sqrt(2). Dilution adjustment was performed using the formula $P_c = P[(1.015 - 1)/(SG - 1)]$, where P_c is the specific gravity-corrected biomarker concentration, P is the observed biomarker concentration, SG is the specific gravity of the urine sample, and 1.015 is the median SG of the study population (31,32). The analysis of blinded specimens by the CDC laboratory was determined not to constitute engagement in human subjects' research.

Statistical Analysis

Generalized estimating equations (GEE) were used to jointly estimate the influence of EDC biomarker concentrations at B1 and B4 on breast density measurements, including: total breast volume, absolute FGV, and percent FGV. This non-conventional application of GEE models allows for the simultaneous modeling of the associations with B1 and B4 EDC biomarker concentrations, with a working independence assumption and model based standard errors (33,34). Breast density measurements were log-transformed prior to analysis. Time-varying associations between EDC biomarker concentrations and breast density were investigated by evaluating the significance of the interaction between biomarker concentrations and Tanner stage at biomarker measurement on breast density. Reported associations were stratified by Tanner stage if significant statistical interaction was detected (Wald test; $p < 0.05$). To account for potential non-linear associations, we modeled tertiles of EDC biomarker concentrations, with tertile cut-points stratified by Tanner stage. Multivariate Wald tests were used to assess whether breast composition was significantly different between any tertile of EDC biomarker concentrations ("overall test"). Significant trends across categories were evaluated by modeling the log-transformed median biomarker concentration within tertiles as a continuous variable. All models were adjusted for age at

B1 EDC biomarker measurement, age at B4 EDC biomarker measurement, BMI Z-score at B1, and BMI Z-score at B4. Models were additionally adjusted for maternal education as an indicator of socio-economic status, which has been related to both exposure profile and breast density (35–38). Associations between breast density measurements and biomarker concentrations were reported as the relative change in geometric mean and 95% confidence interval (CI) by exponentiating the associations with log-transformed breast density measurement. Least-square means were used to visualize the absolute change in breast density measurements between tertiles of EDC biomarker concentrations in adjusted GEE models. For significant (overall test, $p < 0.05$) non-monotonic associations between EDC biomarker concentration and breast density, we additionally modeled urinary biomarker concentrations continuously, including a main effect and interaction with each of the other quantified biomarkers (dichotomized by mean). For models significantly improved by the inclusion of another EDC biomarker and the relevant interaction term (multivariate Wald test, $p < 0.01$), we reported the stratum-specific associations. All statistical analyses were performed in R Version 3.3.1 and figures were generated using ggplot2 (39).

RESULTS

Urinary concentrations of 26 phenol and phthalate biomarkers were quantified in 200 Chilean adolescent girls at breast Tanner stages B1 and B4 as previously described (40). Data analysis was restricted to the subset of 21 biomarkers that were detected in at least 75% of the girls at both time points. In this subset of the ongoing Growth and Obesity Cohort Study (GOCS), urine samples were obtained during B1 between the ages of 6.7 and 9.6 years, with a median collection age of 7.9 years. Urine B4 samples were collected between the ages of 9.4 and 13.1 years, with a median age of 11.2 years (40). The time between EDC biomarker measurements in this cohort ranged from 2 to 5 years. Correlations between B1 and B4 EDC biomarker concentrations in these girls were moderate to weak, reflecting changes in exposure profiles over time (40). On average, biomarker concentrations at B4 were slightly lower than at B1, paralleling a similar trend observed among adolescent U.S. girls of the same age participating in the National Health and Nutrition Examination Survey (40). Furthermore, the correlation between individual biomarkers varied by Tanner stage (Supplemental Figures 1 and 2). Approximately 90% of the girls reached menarche after the first visit establishing B4 ($n=179$). No EDC biomarker, measured at Tanner 1 or Tanner 4, was significantly ($p < 0.05$) associated with the occurrence of menarche prior to the first observed visit of B4. The median BMI Z-score at B1 urine collection was -0.1 (range: $-2.6, 2.1$), and 0.1 (range: $-2.1, 2.3$) at breast density measurement. Approximately 23% of the mothers had post-secondary education (40).

Total Breast Volume

Monocarboxyisononyl phthalate (MCNP) was the only biomarker significantly associated with total breast volume (BV), adjusting for age and BMI Z-score at biomarker measurement, as well as maternal education (overall test, $p < 0.05$; Table 1). While BV among girls in the middle tertile was not significantly different from those in the lowest, volume was 10% greater in the highest tertile compared to the middle tertile (1.10; 95% CI: 1.02, 1.18; Table 1 and Figure 1a). We hypothesized that this non-monotonic u-shaped

association may indicate an interaction between MCNP and another EDC on BV. Therefore, we analyzed the influence of adding a main effect and interaction with each of the other biomarkers. Adding dichotomized (relative to the median) MEP concentrations and an interaction with continuous MCNP concentrations significantly improved model fit ($p < 0.01$, multivariate Wald tests; Supplemental Table 1). Among girls with high MEP concentrations, a one log(ng/ml) increase in MCNP was associated with a 6% increase in BV (1.06; 95% CI: 1.01, 1.10). We additionally detected a significant trend across tertiles of 2,4-dichlorophenol concentrations; girls in the highest tertile had 9% lower geometric mean breast volume than girls in the lowest tertile (0.91; 95% CI: 0.84, 0.99). However, the overall test of whether BV significantly varied between categories of 2,4-dichlorophenol concentrations was not significant.

Fibroglandular Volume

A few distinct biomarkers were associated with dense breast volume (FGV), including MEP, mono-isobutyl phthalate (MiBP), and bisphenol A (BPA; Table 2 and Table 3 and Figure 1b). For MEP and MiBP, the association with FGV was modified by the time of biomarker measurement (Table 3). Concentrations of MEP were moderately correlated between the two Tanner stages (Spearman $\rho = 0.325$) (40). However, MEP specific gravity-adjusted geometric mean concentration was nearly 20 ng/ml higher at B1 than B4 (40). Concentrations of MiBP did not significantly differ between Tanner stages, and were moderately correlated between B1 and B4 (Spearman $\rho = 0.279$) (40). After stratifying by Tanner stage at biomarker measurement, tertiles of MiBP concentration were not significantly associated with FGV (overall test; Table 3). Distinctly, B4 MEP concentrations had a positive association with FGV (trend test, $p = 0.004$). Girls with MEP concentrations in the highest tertile at B4 had a 22% higher geometric mean volume than girls with MEP levels in the first tertile (1.22; 95% CI: 1.06, 1.40). In contrast, BPA had a clear non-linear association with dense volume across Tanner stages. Girls in the middle tertile of BPA concentrations had at least 10% lower FGV than girls in either the lowest or highest tertiles (Table 2). BPA significantly interacted with MEP to influence dense volume, potentially contributing to this non-monotonic association ($p < 0.01$, multivariate Wald tests for added biomarker and interaction; Supplemental Table 1). BPA was only significantly associated with FGV among girls with relatively low concentrations of MEP. A one log(ng/ml) increase in BPA was associated with a 7% decrease in geometric mean FGV among those with low concentrations of MEP (0.93; 95% CI: 0.87, 1.00).

Percent Fibroglandular Volume

While MCNP was only significantly associated with BV, we observed a similarly shaped trend with dense volume. Conversely, MEP and BPA were only associated with FGV. Considering this discordance, we would expect MEP and BPA to be associated with percent dense breast (%FGV). In both cases, the association with %FGV was similar to the association with dense volume (Table 4 and Table 5; Figure 1c). An increase in B4 concentrations of MEP were associated with greater %FGV (Table 5). Paralleling the FGV association, girls with concentrations of BPA in the middle tertile had significantly lower %FGV than girls in the highest or lowest tertiles (Table 4). Percent FGV also had a significant relationship with monocarboxyisooctyl phthalate (MCOP; Table 4). Compared to

girls in the first tertile, those in the highest tertile of MCOP concentrations had 7% higher %FGV (1.07; 95% CI: 1.01, 1.14). While the associations between this biomarker and FGV were not significant, the association trended in the same direction as with %FGV. The association between MCOP and %FGV was significantly modified by the occurrence of menarche prior to breast density measurement (Yes/No; Supplemental Table 2). The analysis restricted to girls that attained menarche after breast density measurement trended in a similar direction. However, the overall test of whether %FGV varied between MCOP tertiles was no longer significant. Monomethyl phthalate (MMP) similarly demonstrated a positive association with %FGV (trend $p=0.032$). However, the overall test that tertiles of MMP concentration improved model fit for %FGV did not reach significance.

DISCUSSION

This is the first investigation of the impact of childhood and adolescent exposure to phenols and phthalates on pubertal breast density. While the correlations between the EDC biomarkers measured at B1 and B4 were low, the associations between these biomarkers and breast density were relatively consistent over time. The only two exceptions were the diethyl phthalate (DEP) metabolite, MEP, and the diisobutyl phthalate biomarker, MiBP. Only B4 biomarker concentrations of MEP were significantly associated with FGV. We speculate that the mechanism of action of MEP may depend on a threshold level of specific endogenous hormones, such as estradiol. *In vitro*, DEP causes significant proliferation of human breast cancer cell lines through activation of estrogen-receptor alpha (41,42). Based on recombinant yeast screen assays, DEP has been shown to have weak estrogenic potential (43).

A few biomarkers demonstrated a non-linear association with breast volume and density, including BPA and MCNP. Non-monotonic dose-response relationships are relatively commonplace among *in vitro* and *in vivo* experimental studies of the health effects of EDC exposure (44). There are a number of mechanisms that may contribute to these phenomena, including multiple target receptors with different binding affinities and opposing action, stimulating negative feedback, and receptor desensitization. In the case of BPA and MCNP, these non-monotonic associations reflected a significant interaction with another biomarker on breast composition, notably MEP. MCNP was only positively associated with BV among girls with high concentrations of MEP relative to the median. The relationship between FGV and BPA was inverted among girls with low concentrations of MEP. Concentrations of BPA and MEP, and MCOP and MEP were not correlated in this population, suggesting disparate routes of exposure. A common source of DEP, the parent compound of MEP is personal care product use (45,46). Given this unique exposure route, the observed statistical interactions with MEP may reflect unmeasured confounding by an element of hygiene routine. To address this question, future studies could be useful to disentangle specific routes of EDC exposure for Latina girls, which may greatly vary from U.S. or European populations.

Prior studies have suggested that childhood and adolescent levels of exogenous and endogenous sex hormones are associated with breast density. Compared to women who started hormonal contraceptives at older ages (22–28 years), initiation of hormonal contraceptive use between the ages of 12–17 years has been associated with higher young

adult breast density (47). Prior to menarche, higher serum levels of dehydroepiandrosterone sulfate and sex hormone-binding globulin have also been positively associated with young adult breast density (48). This earlier study did not report a significant association with adolescent levels of estrogens, progesterone, androstenedione, or testosterone before or after menarche (48). Currently, little is known about how EDCs may interact with endogenous hormone levels in adolescent girls. One small study of 84 girls in Copenhagen found mono-n-butyl phthalate (MBP) was inversely associated (albeit not significantly) with adrenal androgens at age 13 (49). In our study, MBP was not significantly associated with breast density measurements. Research to assess whether endogenous hormone levels may interact with both phenol and phthalate biomarkers during puberty would increase our understanding of the potential implications for breast development.

Only one prior cross-sectional study has examined the association between EDC biomarker concentrations and breast density (50). This earlier study found a positive association between serum BPA and MEP and %FGV among approximately 250 postmenopausal women. A major criticism of this prior study was the use of serum biomarkers, which are more sensitive to contamination (51). However, these influences were likely to result in non-differential measurement error, and were postulated to bias associations towards the null. Urinary concentrations of MEP were associated with increased odds of breast cancer among Mexican women (21). Mirroring these findings, we report a positive association between B4 MEP urinary concentrations and adolescent breast density. In contrast, BPA had a non-monotonic association with breast density in our study, possibly reflecting an interaction with MEP concentrations. Both of the prior investigations were restricted to a subset of the phenols and phthalates biomarkers evaluated in this study. Therefore, it is possible that some of the additional associations observed in the present study would have been observed at other ages. Alternatively, breast tissue may have specific windows of susceptibility to certain EDCs.

One limitation of our study was the use of a single urine measurement at each developmental stage to estimate EDC exposure given the short half-life of these biomarkers. Nevertheless, due to chronic and repetitive exposures, prior longitudinal assessments have suggested that relative EDC exposures over several months (to possibly a year) can be reasonably estimated based on a single spot sample (51–54). Potential measurement error in exposure is compensated by our longitudinal assay of urinary phenol and phthalate biomarker concentrations. Puberty reflects a period of rapid physical and social change that may influence both exposure profile and modulate the impact of these compounds on developing mammary tissue. Another strength is the focus on Latina girls. A study of similarly aged U.S. girls showed differences in the urinary biomarker concentrations of phenols and phthalates by race/ethnicity (55). In addition to disparities in exposure profile, the U.S. cohort also reported an earlier age of thelarche among Hispanic girls compared to non-Hispanic white girls, indicating potential biological differences in breast development (56). The consequential drawback is that the findings of our study may not be generalizable to all race/ethnicities. Concentrations of BPA in this population were lower than similarly aged U.S. girls (57,58), but only slightly lower than a cohort of girls in Mexico City (59). In contrast, concentrations of MEP were much higher in this cohort compared to U.S. girls (58), with a similar distribution detected in the Hispanic study (59). These discrepancies

highlight potential differences in exposure profile between populations. Finally, we recommend cautious interpretation of the weaker pairwise comparisons of breast composition between tertiles of the many EDC biomarkers quantified. In our discussion of the results, we have chosen to highlight the stronger associations that are less likely due to chance. We encourage replication of these analyses in independent cohorts to validate these findings and to appraise population-specific sensitivities.

Higher estrogenic activity in childhood has previously been associated with early breast development in the GOCS cohort (60). Given these prior findings were independent of central activation or peripheral estrogen conversion associated with obesity, it was postulated that this estrogenic activity may reflect EDC action (60). This study suggests that the developing breast tissue of Latina girls is responsive to exogenous hormones during childhood and adolescence. Future studies would be useful to assess whether these shifts in pubertal breast density track through the life course to modify breast cancer risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

The authors wish to express their gratitude to Manori Silva, Ella Samandar, Jim Preau, Prabha Dwivedi, Xiaoliu Zhou, and Tao Jia who performed the measurements of phthalates and phenols biomarkers.

Financial Support: This work was supported by Public Health Service grant R01CA158313 from the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (to KBM). This publication was also partially made possible by the Breast Cancer and the Environment Research Program (BCERP) award number U01ES026130 from the National Institute of Environmental Health Sciences (NIEHS) and the National Cancer Institute (NCI), NIH, DHHS (to KBM).

REFERENCES

1. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.* 2006;15:1159–69.
2. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. *N Engl J Med.* 2007;356:227–36. [PubMed: 17229950]
3. Yaghjian L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. *J Natl Cancer Inst.* 2011;103:1179–89. [PubMed: 21795664]
4. Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.* 2005;14:343–9.
5. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. *Breast Cancer Res BCR.* 2008;10:201. [PubMed: 18226174]
6. Samimi G, Colditz GA, Baer HJ, Tamimi RM. Measures of energy balance and mammographic density in the Nurses' Health Study. *Breast Cancer Res Treat.* 2008;109:113–22. [PubMed: 17592770]
7. Harris HR, Tamimi RM, Willett WC, Hankinson SE, Michels KB. Body size across the life course, mammographic density, and risk of breast cancer. *Am J Epidemiol.* 2011;174:909–18. [PubMed: 21911827]

8. Kusano AS, Trichopoulos D, Terry KL, Chen WY, Willett WC, Michels KB. A prospective study of breast size and premenopausal breast cancer incidence. *Int J Cancer*. 2006;118:2031–4. [PubMed: 16284954]
9. Hsieh CC, Trichopoulos D. Breast size, handedness and breast cancer risk. *Eur J Cancer Oxf Engl* 1990. 1991;27:131–5.
10. Novotny R, Daida Y, Morimoto Y, Shepherd J, Maskarinec G. Puberty, body fat, and breast density in girls of several ethnic groups. *Am J Hum Biol Off J Hum Biol Counc*. 2011;23:359–65.
11. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. “Hormonal” risk factors, “breast tissue age” and the age-incidence of breast cancer. *Nature*. 1983;303:767–70. [PubMed: 6866078]
12. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 1995;4:567–71.
13. Boyd N, Martin L, Chavez S, Gunasekara A, Salleh A, Melnichouk O, et al. Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. *Lancet Oncol*. 2009;10:569–80. [PubMed: 19409844]
14. Biro FM, Pinney SM, Huang B, Baker ER, Walt Chandler D, Dorn LD. Hormone changes in peripubertal girls. *J Clin Endocrinol Metab*. 2014;99:3829–35. [PubMed: 25029416]
15. Diamanti-Kandarakis E, Bourguignon J-P, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. *Endocr Rev*. 2009;30:293–342. [PubMed: 19502515]
16. Hauser R, Calafat AM. Phthalates and human health. *Occup Environ Med*. 2005;62:806–18. [PubMed: 16234408]
17. Philippat C, Mortamais M, Chevrier C, Petit C, Calafat AM, Ye X, et al. Exposure to phthalates and phenols during pregnancy and offspring size at birth. *Environ Health Perspect*. 2012;120:464–70. [PubMed: 21900077]
18. Meeker JD. Exposure to environmental endocrine disruptors and child development. *Arch Pediatr Adolesc Med*. 2012;166:952–8. [PubMed: 23367522]
19. Wolff MS, Teitelbaum SL, McGovern K, Windham GC, Pinney SM, Galvez M, et al. Phthalate exposure and pubertal development in a longitudinal study of US girls. *Hum Reprod Oxf Engl*. 2014;29:1558–66.
20. Wolff MS, Teitelbaum SL, McGovern K, Pinney SM, Windham GC, Galvez M, et al. Environmental phenols and pubertal development in girls. *Environ Int*. 2015;84:174–80. [PubMed: 26335517]
21. López-Carrillo L, Hernández-Ramírez RU, Calafat AM, Torres-Sánchez L, Galván-Portillo M, Needham LL, et al. Exposure to Phthalates and Breast Cancer Risk in Northern Mexico. *Environ Health Perspect*. 2010;118:539–44. [PubMed: 20368132]
22. Shepherd JA, Malkov S, Fan B, Laidevant A, Novotny R, Maskarinec G. Breast density assessment in adolescent girls using dual-energy X-ray absorptiometry: a feasibility study. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2008;17:1709–13.
23. Tanner J *Growth at adolescence*. Oxford: Blackwell Scientific Publications; 1962.
24. Shepherd JA, Herve L, Landau J, Fan B, Kerlikowske K, Cummings SR. Clinical comparison of a novel breast DXA technique to mammographic density. *Med Phys*. 2006;33:1490–8. [PubMed: 16752583]
25. Weaver CM, McCabe LD, McCabe GP, Novotny R, Van Loan M, Going S, et al. Bone mineral and predictors of bone mass in white, Hispanic, and Asian early pubertal girls. *Calcif Tissue Int*. 2007;81:352–63. [PubMed: 17989943]
26. Shepherd JA, Kerlikowske KM, Smith-Bindman R, Genant HK, Cummings SR. Measurement of breast density with dual X-ray absorptiometry: feasibility. *Radiology*. 2002;223:554–7. [PubMed: 11997567]
27. Samandar E, Silva MJ, Reidy JA, Needham LL, Calafat AM. Temporal stability of eight phthalate metabolites and their glucuronide conjugates in human urine. *Environ Res*. 2009;109:641–6. [PubMed: 19272594]

28. Ye X, Bishop AM, Reidy JA, Needham LL, Calafat AM. Temporal stability of the conjugated species of bisphenol A, parabens, and other environmental phenols in human urine. *J Expo Sci Environ Epidemiol*. 2007;17:567–72. [PubMed: 17410114]
29. Ye X, Kuklennyik Z, Needham LL, Calafat AM. Automated on-line column-switching HPLC-MS/MS method with peak focusing for the determination of nine environmental phenols in urine. *Anal Chem*. 2005;77:5407–13. [PubMed: 16097788]
30. Silva MJ, Samandar E, Preau JL, Reidy JA, Needham LL, Calafat AM. Quantification of 22 phthalate metabolites in human urine. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2007;860:106–12.
31. Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. *Am Ind Hyg Assoc J*. 1993;54:615–27. [PubMed: 8237794]
32. Teass AW, Biagini RE, DeBord G, Hull RD. Application of Biological Monitoring Methods NIOSH Man Anal Method. Cincinnati: National Institute for Occupational Safety and Health Division of Physical Sciences and Engineering; 1998.
33. Sánchez BN, Hu H, Litman HJ, Téllez-Rojo MM. Statistical methods to study timing of vulnerability with sparsely sampled data on environmental toxicants. *Environ Health Perspect*. 2011;119:409–15. [PubMed: 21362588]
34. Chen Y-H, Ferguson KK, Meeker JD, McElrath TF, Mukherjee B. Statistical methods for modeling repeated measures of maternal environmental exposure biomarkers during pregnancy in association with preterm birth. *Environ Health Glob Access Sci Source*. 2015;14:9.
35. Tyrrell J, Melzer D, Henley W, Galloway TS, Osborne NJ. Associations between socioeconomic status and environmental toxicant concentrations in adults in the USA: NHANES 2001–2010. *Environ Int*. 2013;59:328–35. [PubMed: 23892225]
36. Kobrosly RW, Parlett LE, Stahlhut RW, Barrett ES, Swan SH. Socioeconomic factors and phthalate metabolite concentrations among United States women of reproductive age. *Environ Res*. 2012;115:11–7. [PubMed: 22472009]
37. Tehranifar P, Cohn BA, Flom JD, Protacio A, Cirillo P, Lumey LH, et al. Early life socioeconomic environment and mammographic breast density. *BMC Cancer*. 2017;17:41. [PubMed: 28068940]
38. Akinyemiju TF, Tehranifar P, Flom JD, Liao Y, Wei Y, Terry MB. Early life growth, socioeconomic status, and mammographic breast density in an urban US birth cohort. *Ann Epidemiol*. 2016;26:540–545.e2. [PubMed: 27497679]
39. Wickham H *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag; 2009.
40. Binder AM, Corvalan C, Calafat AM, Ye X, Mericq V, Pereira A, et al. Childhood and adolescent phenol and phthalate exposure and the age of menarche in Latina girls. *Environ Health Glob Access Sci Source*. 2018;17:32.
41. Hong E-J, Ji Y-K, Choi K-C, Manabe N, Jeung E-B. Conflict of estrogenic activity by various phthalates between in vitro and in vivo models related to the expression of Calbindin-D9k. *J Reprod Dev*. 2005;51:253–63. [PubMed: 15883486]
42. Kumar N, Sharan S, Srivastava S, Roy P. Assessment of estrogenic potential of diethyl phthalate in female reproductive system involving both genomic and non-genomic actions. *Reprod Toxicol Elmsford N*. 2014;49:12–26.
43. Harris CA, Henttu P, Parker MG, Sumpter JP. The estrogenic activity of phthalate esters in vitro. *Environ Health Perspect*. 1997;105:802–11. [PubMed: 9347895]
44. Lagarde F, Beausoleil C, Belcher SM, Belzunces LP, Emond C, Guerbet M, et al. Non-monotonic dose-response relationships and endocrine disruptors: a qualitative method of assessment. *Environ Health*. 2015; 14: 13. [PubMed: 25971433]
45. Konecki D, Wang R, Moody RP, Zhu J. Phthalates in cosmetic and personal care products: concentrations and possible dermal exposure. *Environ Res*. 2011;111:329–36. [PubMed: 21315328]
46. Harley KG, Kogut K, Madrigal DS, Cardenas M, Vera IA, Meza-Alfaro G, et al. Reducing Phthalate, Paraben, and Phenol Exposure from Personal Care Products in Adolescent Girls: Findings from the HERMOSA Intervention Study. *Environ Health Perspect*. 2016;124:1600–7. [PubMed: 26947464]

47. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, et al. Menstrual and reproductive characteristics and breast density in young women. *Cancer Causes Control CCC*. 2013;24:1973–83. [PubMed: 23933948]
48. Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, et al. Adolescent endogenous sex hormones and breast density in early adulthood. *Breast Cancer Res BCR*. 2015;17:77. [PubMed: 26041651]
49. Mouritsen A, Frederiksen H, Sørensen K, Aksglaede L, Hagen C, Skakkebaek NE, et al. Urinary phthalates from 168 girls and boys measured twice a year during a 5-year period: associations with adrenal androgen levels and puberty. *J Clin Endocrinol Metab*. 2013;98:3755–64. [PubMed: 23824423]
50. Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JD, Hampton JM, et al. Circulating serum xenoestrogens and mammographic breast density. *Breast Cancer Res BCR*. 2013;15:R45. [PubMed: 23710608]
51. Calafat AM, Longnecker MP, Koch HM, Swan SH, Hauser R, Goldman LR, et al. Optimal Exposure Biomarkers for Nonpersistent Chemicals in Environmental Epidemiology. *Environ Health Perspect*. 2015;123:A166–168. [PubMed: 26132373]
52. Johns LE, Cooper GS, Galizia A, Meeker JD. Exposure Assessment Issues in Epidemiology Studies of Phthalates. *Environ Int*. 2015;85:27–39. [PubMed: 26313703]
53. Teitelbaum SL, Britton JA, Calafat AM, Ye X, Silva MJ, Reidy JA, et al. Temporal variability in urinary concentrations of phthalate metabolites, phytoestrogens and phenols among minority children in the United States. *Environ Res*. 2008;106:257–69. [PubMed: 17976571]
54. Engel LS, Buckley JP, Yang G, Liao LM, Satagopan J, Calafat AM, et al. Predictors and Variability of Repeat Measurements of Urinary Phenols and Parabens in a Cohort of Shanghai Women and Men. *Environ Health Perspect*. 2014;122:733–40. [PubMed: 24659570]
55. Wolff MS, Teitelbaum SL, Pinney SM, Windham G, Liao L, Biro F, et al. Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls. *Environ Health Perspect*. 2010;118:1039–46. [PubMed: 20308033]
56. Biro FM, Greenspan LC, Galvez MP, Pinney SM, Teitelbaum S, Windham GC, et al. Onset of breast development in a longitudinal cohort. *Pediatrics*. 2013;132:1019–27. [PubMed: 24190685]
57. Buttke DE, Sircar K, Martin C. Exposures to endocrine-disrupting chemicals and age of menarche in adolescent girls in NHANES (2003–2008). *Environ Health Perspect*. 2012;120:1613–8. [PubMed: 23124194]
58. Wolff MS, Pajak A, Pinney SM, Windham GC, Galvez M, Rybak M, et al. Associations of urinary phthalate and phenol biomarkers with menarche in a multiethnic cohort of young girls. *Reprod Toxicol Elmsford N*. 2017;67:56–64.
59. Watkins DJ, Téllez-Rojo MM, Ferguson KK, Lee JM, Solano-Gonzalez M, Blank-Goldenberg C, et al. In utero and peripubertal exposure to phthalates and BPA in relation to female sexual maturation. *Environ Res*. 2014;134:233–41. [PubMed: 25173057]
60. Pereira A, Corvalán C, Uauy R, Klein KO, Mericq V. Ultrasensitive estrogen levels at 7 years of age predict earlier thelarche: evidence from girls of the growth and obesity Chilean cohort. *Eur J Endocrinol*. 2015;173:835–42. [PubMed: 26369578]




Figure 1.

Changes in breast density associated with urinary phenol and phthalate biomarker concentrations. T1= lowest tertile; T2=middle tertile, T3=highest tertile. Plotting the least-square means and associated 95% CI of a.) breast volume, b.) fibroglandular volume, and c.) %FGV between tertiles of biomarker concentrations based on GEE models adjusting for age at B1 biomarker measurement, age at B4 biomarker measurement, BMI z-score at B1, BMI z-score at B4, and maternal education. Significant difference ($p < 0.05$) between: tertiles T1

and T2 indicated by A, tertiles T2 and T3 indicated by B, and tertiles T1 and T3 indicated by C.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Relative shift in geometric mean (95% CI) breast volume between tertiles of each phenol and phthalate biomarker across B1 and B4^a

EDC	Overall Test ^b (p-value)	Middle vs Lowest Tertile (ref)	Highest vs Lowest Tertile (ref)	Highest vs Middle Tertile (ref)	Trend ^c (p-value)
2,4-dichlorophenol	0.108	0.97 (0.89, 1.05)	0.91* (0.84, 0.99)	0.94 (0.86, 1.03)	0.032*
2,5-dichlorophenol	0.198	1.02 (0.93, 1.11)	1.07 (0.99, 1.16)	1.05 (0.97, 1.13)	0.057
Benzophenone-3	0.695	1.03 (0.95, 1.11)	1.03 (0.96, 1.12)	1.01 (0.94, 1.09)	0.380
BPA	0.356	0.95 (0.88, 1.02)	0.96 (0.88, 1.05)	1.02 (0.94, 1.11)	0.448
Methyl paraben	0.679	0.97 (0.89, 1.05)	0.99 (0.91, 1.08)	1.03 (0.95, 1.11)	0.804
MBP	0.329	0.95 (0.88, 1.02)	0.97 (0.90, 1.04)	1.02 (0.95, 1.10)	0.453
MBzP	0.184	0.93 (0.87, 1.01)	0.95 (0.87, 1.04)	1.02 (0.94, 1.10)	0.243
MCNP	0.043*	0.94 (0.86, 1.02)	1.03 (0.96, 1.10)	1.10* (1.02, 1.18)	0.369
MCOP	0.852	1.03 (0.94, 1.12)	1.02 (0.94, 1.10)	0.99 (0.91, 1.08)	0.706
MCCP	0.708	0.97 (0.90, 1.06)	1.01 (0.94, 1.09)	1.04 (0.95, 1.13)	0.766
MECPP	0.735	0.97 (0.89, 1.05)	1.00 (0.92, 1.08)	1.03 (0.94, 1.13)	0.936
MEHHP	0.919	0.99 (0.91, 1.08)	1.01 (0.93, 1.09)	1.02 (0.93, 1.11)	0.741
MEHP	0.077	0.92* (0.85, 1.00)	0.93 (0.86, 1.01)	1.01 (0.93, 1.11)	0.108
MEOHP	0.908	0.98 (0.91, 1.07)	0.99 (0.92, 1.07)	1.01 (0.93, 1.09)	0.855
MEP	0.600	1.02 (0.94, 1.12)	1.04 (0.96, 1.14)	1.02 (0.94, 1.11)	0.296
MHBP	0.767	0.97 (0.90, 1.05)	1.00 (0.92, 1.07)	1.02 (0.95, 1.10)	0.902
MHiBP	0.915	0.99 (0.91, 1.06)	1.00 (0.91, 1.09)	1.01 (0.94, 1.09)	0.949
MiBP	0.517	1.04 (0.96, 1.12)	1.00 (0.91, 1.09)	0.96 (0.89, 1.04)	0.967
MMP	0.544	0.97 (0.90, 1.05)	1.02 (0.94, 1.10)	1.05 (0.96, 1.13)	0.716
Propyl paraben	0.811	1.02 (0.94, 1.11)	1.02 (0.94, 1.11)	1.00 (0.92, 1.08)	0.582
Triclosan	0.226	0.96 (0.89, 1.04)	0.93 (0.85, 1.01)	0.96 (0.89, 1.04)	0.070

^aEstimating average association across B1 and B4 EDC measurements using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education

^bOverall test whether EDC category improves model fit (multivariate Wald test)

^cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

* p<0.05,

**p<0.01,

***p<0.001

Table 2.

Relative shift in geometric mean (95% CI) fibroglandular volume between tertiles of each phenol and phthalate biomarker across B1 and B4^a

EDC	Overall Test ^b (p-value)	Middle vs Lowest Tertile (ref)	Highest vs Lowest Tertile (ref)	Highest vs Middle Tertile (ref)	Trend ^c (p-value)
2,4-dichlorophenol	0.269	0.93 (0.84, 1.03)	0.92 (0.82, 1.03)	0.98 (0.88, 1.10)	0.152
2,5-dichlorophenol	0.578	1.05 (0.95, 1.17)	1.05 (0.94, 1.17)	1.00 (0.91, 1.10)	0.382
Benzophenone-3	0.811	1.00 (0.91, 1.11)	1.03 (0.93, 1.14)	1.03 (0.93, 1.13)	0.433
BPA	0.008 **	0.88 ** (0.80, 0.97)	1.01 (0.90, 1.12)	1.14 * (1.03, 1.26)	0.879
Methyl paraben	0.824	0.99 (0.88, 1.10)	1.01 (0.92, 1.12)	1.03 (0.94, 1.13)	0.876
MBP	0.169	0.92 (0.84, 1.00)	0.96 (0.87, 1.06)	1.05 (0.96, 1.15)	0.497
MBzP	0.582	0.95 (0.86, 1.05)	0.99 (0.88, 1.10)	1.04 (0.94, 1.14)	0.763
MCNP	0.080	0.97 (0.88, 1.08)	1.07 (0.97, 1.18)	1.10 * (1.01, 1.20)	0.120
MCOP	0.189	1.04 (0.93, 1.16)	1.09 (0.99, 1.21)	1.05 (0.95, 1.16)	0.073
M CPP	0.854	1.02 (0.92, 1.13)	1.03 (0.93, 1.13)	1.00 (0.90, 1.12)	0.616
ME CPP	0.719	1.01 (0.91, 1.12)	1.05 (0.94, 1.16)	1.04 (0.92, 1.16)	0.374
MEHHP	0.708	0.99 (0.89, 1.11)	1.04 (0.93, 1.15)	1.04 (0.94, 1.16)	0.489
MEHP	0.237	0.91 (0.82, 1.01)	0.98 (0.88, 1.08)	1.07 (0.95, 1.20)	0.715
MEOHP	0.554	0.98 (0.88, 1.08)	1.03 (0.93, 1.15)	1.06 (0.96, 1.17)	0.549
MEP	0.194	1.03 (0.93, 1.14)	1.09 (0.99, 1.21)	1.06 (0.96, 1.17)	0.065
MHBP	0.687	0.97 (0.88, 1.08)	1.01 (0.92, 1.11)	1.04 (0.95, 1.14)	0.772
MHiBP	0.588	0.99 (0.89, 1.10)	1.04 (0.93, 1.16)	1.05 (0.96, 1.15)	0.516
MiBP	0.802	1.03 (0.93, 1.14)	1.03 (0.93, 1.15)	1.00 (0.91, 1.10)	0.489
MMP	0.252	1.02 (0.93, 1.12)	1.08 (0.98, 1.20)	1.06 (0.96, 1.17)	0.116
Propyl paraben	0.812	1.01 (0.91, 1.12)	1.03 (0.94, 1.14)	1.02 (0.93, 1.12)	0.468
Triclosan	0.130	0.91 * (0.83, 1.00)	0.93 (0.83, 1.04)	1.02 (0.92, 1.13)	0.218

^aEstimating average association across B1 and B4 EDC measurements using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education

^bOverall test whether EDC category improves model fit (multivariate Wald test)

^cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

* p<0.05,

** p<0.01,

***p<0.001

Table 3.

Relative shift in geometric mean (95% CI) fibroglandular volume between tertiles of MEP and MiBP concentrations stratified by Tanner stage at EDC measurement^a

EDC	Tanner Stage	Overall Test ^b (p-value)	Middle vs Lowest Tertile (ref)	Highest vs Lowest Tertile (ref)	Highest vs Middle Tertile (ref)	Trend ^c (p-value)
MEP						
	B1	0.590	1.06 (0.92, 1.22)	0.99 (0.85, 1.14)	0.93 (0.81, 1.07)	0.752
	B4	0.006 ^{**}	1.00 (0.88, 1.15)	1.22 ^{**} (1.06, 1.40)	1.21 ^{**} (1.06, 1.39)	0.004 ^{**}
MiBP						
	B1	0.214	0.90 (0.78, 1.04)	1.01 (0.87, 1.16)	1.12 (0.97, 1.29)	0.942
	B4	0.075	1.17 [*] (1.02, 1.35)	1.06 (0.92, 1.22)	0.90 (0.79, 1.04)	0.377

^a Estimating Tanner stage-specific association between EDC metabolite and fibroglandular volume using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education, including an interaction between EDC tertile and Tanner stage; restricted to subset of association for which the interaction with Tanner stage was significant (p<0.05)

^b Overall test whether EDC category improves model fit (Likelihood ratio test)

^c Trend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

* p<0.05,

** p<0.01,

***p<0.001

Table 4.

Relative shift in geometric mean (95% CI) percent fibroglandular volume between tertiles of each phenol and phthalate biomarker across B1 and B4^a

EDC	Overall Test ^b (p-value)	Middle vs Lowest Tertile (ref)	Highest vs Lowest Tertile (ref)	Highest vs Middle Tertile (ref)	Trend ^c (p-value)
2,4-dichlorophenol	0.369	0.96 (0.90, 1.03)	1.00 (0.94, 1.07)	1.04 (0.98, 1.10)	0.872
2,5-dichlorophenol	0.221	1.03 (0.97, 1.10)	0.98 (0.92, 1.05)	0.95 (0.89, 1.01)	0.410
Benzophenone-3	0.707	0.98 (0.92, 1.04)	1.00 (0.94, 1.07)	1.02 (0.96, 1.08)	0.779
BPA	0.003**	0.93* (0.88, 1.00)	1.04 (0.98, 1.11)	1.12*** (1.05, 1.19)	0.210
Methyl paraben	0.802	1.02 (0.95, 1.09)	1.02 (0.96, 1.09)	1.00 (0.95, 1.05)	0.635
MBP	0.422	0.96 (0.91, 1.02)	1.00 (0.93, 1.06)	1.03 (0.97, 1.10)	0.848
MBzP	0.612	1.02 (0.95, 1.09)	1.04 (0.97, 1.11)	1.02 (0.96, 1.08)	0.363
MCNP	0.408	1.04 (0.97, 1.11)	1.04 (0.98, 1.11)	1.00 (0.95, 1.06)	0.203
MCOP	0.039*	1.01 (0.95, 1.07)	1.07* (1.01, 1.14)	1.06* (1.00, 1.12)	0.022*
MCCP	0.354	1.05 (0.98, 1.12)	1.02 (0.96, 1.08)	0.97 (0.91, 1.03)	0.664
MECPP	0.305	1.04 (0.98, 1.10)	1.05 (0.98, 1.12)	1.00 (0.94, 1.07)	0.195
MEHHP	0.726	1.00 (0.94, 1.06)	1.02 (0.96, 1.09)	1.02 (0.96, 1.09)	0.486
MEHP	0.265	1.00 (0.93, 1.07)	1.04 (0.98, 1.12)	1.05 (0.98, 1.12)	0.168
MEOHP	0.343	0.99 (0.93, 1.05)	1.04 (0.97, 1.11)	1.05 (0.98, 1.12)	0.229
MEP	0.352	1.01 (0.94, 1.08)	1.05 (0.98, 1.12)	1.04 (0.98, 1.11)	0.172
MHBP	0.787	1.00 (0.94, 1.07)	1.02 (0.96, 1.09)	1.02 (0.96, 1.08)	0.566
MHiBP	0.412	1.00 (0.94, 1.07)	1.04 (0.97, 1.12)	1.04 (0.98, 1.10)	0.264
MiBP	0.432	0.99 (0.93, 1.07)	1.03 (0.97, 1.10)	1.04 (0.98, 1.11)	0.336
MMP	0.083	1.05 (0.99, 1.11)	1.07* (1.01, 1.13)	1.02 (0.96, 1.08)	0.032*
Propyl paraben	0.785	0.98 (0.92, 1.05)	1.00 (0.95, 1.07)	1.02 (0.96, 1.08)	0.727
Triclosan	0.125	0.95 (0.89, 1.01)	1.00 (0.94, 1.07)	1.05 (0.99, 1.12)	0.853

^aEstimating average association across B1 and B4 EDC measurements using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education

^bOverall test whether EDC category improves model fit (multivariate Wald test)

^cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

* p<0.05,

** p<0.01,

***p<0.001

Table 5.

Relative shift in geometric mean (95% CI) percent fibroglandular volume between tertiles of MEP concentrations stratified by Tanner stage at EDC measurement^a

EDC	Tanner Stage	Overall Test ^b (p-value)	Middle vs Lowest Tertile (ref)	Highest vs Lowest Tertile (ref)	Highest vs Middle Tertile (ref)	Trend ^b (p-value)
MEP						
	B1	0.742	1.03 (0.94, 1.12)	1.00 (0.91, 1.09)	0.97 (0.89, 1.06)	0.875
	B4	0.026 [*]	0.99 (0.91, 1.07)	1.10 [*] (1.01, 1.20)	1.12 [*] (1.02, 1.22)	0.024 [*]

^aEstimating Tanner stage-specific association between EDC metabolite and percent fibroglandular volume using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education, including an interaction between EDC tertile and Tanner stage; restricted to subset of association for which the interaction with Tanner stage was significant (p<0.05)

^bOverall test whether EDC category improves model fit (Likelihood ratio test)

^cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable

* p<0.05,

**p<0.01,

***p<0.001